International Clinical Trial: Phase III Study of Becotatug vedotin Combined with a PD-1 Inhibitor versus PD-1 Inhibitor Monotherapy in EGFR-Positive and CPS = 1 Resectable Locally Advanced Head and Neck Squamous Cell Carcinoma: A Multicenter, Randomized Controlled Trial

Geneva, May 29 -- International Clinical Trials Registry received information related to the study (ChiCTR2600125057) titled 'Phase III Study of Becotatug vedotin Combined with a PD-1 Inhibitor versus PD-1 Inhibitor Monotherapy in EGFR-Positive and CPS = 1 Resectable Locally Advanced Head and Neck Squamous Cell Carcinoma: A Multicenter, Randomized Controlled Trial' on May 20.

Study Type: Interventional study

Study Design: Parallel

Primary Sponsor: Fifth Affiliated Hospital, Sun Yat-Sen University

Condition: head and neck squamous cell carcinoma (oral cavity, oropharynx, hypopharynx, or larynx)

Intervention: Experimental group:Becotatug vedotin plus pucotenlimab neoadjuvant therapy, radical surgery, postoperative adjuvant radiother...